Cellid Past Earnings Performance
Past criteria checks 0/6
Cellid's earnings have been declining at an average annual rate of -33.7%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 39% per year.
Key information
-33.7%
Earnings growth rate
-31.1%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 39.0% |
| Return on equity | -28.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Cellid makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -11,611 | 4,783 | 5,039 |
| 30 Sep 23 | 480 | -13,804 | 4,867 | 4,708 |
| 30 Jun 23 | 480 | -14,889 | 4,627 | 6,013 |
| 31 Mar 23 | 480 | -21,585 | 4,764 | 6,356 |
| 31 Dec 22 | 480 | -22,865 | 4,702 | 7,886 |
| 30 Sep 22 | 0 | -24,131 | 5,089 | 9,973 |
| 30 Jun 22 | 0 | -22,460 | 5,037 | 9,150 |
| 31 Mar 22 | 909 | -15,000 | 4,625 | 8,879 |
| 31 Dec 21 | 909 | -13,071 | 4,383 | 7,426 |
| 30 Sep 21 | 909 | -9,830 | 3,668 | 5,762 |
| 30 Jun 21 | 909 | -8,126 | 3,092 | 5,121 |
| 31 Mar 21 | 0 | -5,661 | 2,000 | 3,794 |
| 31 Dec 20 | 0 | -4,126 | 1,602 | 3,173 |
| 30 Sep 20 | 0 | -3,276 | 1,368 | 2,507 |
| 30 Jun 20 | 0 | -2,663 | 1,136 | 2,417 |
| 31 Mar 20 | 0 | -3,428 | 1,654 | 2,598 |
| 31 Dec 19 | 0 | -2,494 | 1,375 | 2,063 |
| 30 Sep 19 | 0 | -2,680 | 1,138 | 2,372 |
| 30 Jun 19 | 0 | -2,596 | 952 | 2,216 |
| 31 Mar 19 | 0 | -4,427 | 723 | 1,762 |
| 31 Dec 18 | 0 | -11,286 | 606 | 1,758 |
| 30 Sep 18 | 0 | -11,655 | 459 | 1,233 |
| 30 Jun 18 | 0 | -12,752 | 414 | 1,327 |
| 31 Mar 18 | 0 | -11,443 | 402 | 1,279 |
| 31 Dec 17 | 0 | -5,408 | 323 | 1,164 |
Quality Earnings: A299660 is currently unprofitable.
Growing Profit Margin: A299660 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A299660 is unprofitable, and losses have increased over the past 5 years at a rate of 33.7% per year.
Accelerating Growth: Unable to compare A299660's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A299660 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A299660 has a negative Return on Equity (-28.67%), as it is currently unprofitable.